Navigation Links
Clinical Trial Demonstrates That EarlySense May Be An Effective Indicator for Respiratory Pattern Recognition
Date:1/13/2014

WALTHAM, Mass., Jan. 13, 2014 /PRNewswire/ -- EarlySense, the market leader in Proactive Patient Care Solutions, announced today the results of a small clinical trial conducted at Brigham and Women's Hospital in Boston that identifies complex respiratory patterns which were found to be correlated to patients' respiratory condition and have the potential to show when mechanical ventilation is no longer required.

"The study results show that unique, complex respiratory patterns have the potential to predict, on one hand, the patients' readiness to be separated from the ventilator, but, alternately, also the need for continued ventilatory support," said Dr. Gyorgy Frendl, MD, PhD, Director of Surgical Critical Care Research, Brigham and Women's Hospital, Assistant Professor of Anesthesia, Harvard Medical School, the Principal Investigator of the study. "For patients recently weaned from the ventilator, the appearance of these complex distress respiratory patterns indicated that they were likely to require further ventilator support:

  • Generalized disorganized respirations
  • Frequent [every 30-120 seconds] high amplitude gasping breaths
  • Periods of apnea >30 seconds

For ventilated patients, the above patterns indicated that the patient is not yet ready to be separated from the mechanical ventilator support.

"The ability to measure advanced respiratory patterns in a contact-free manner is a promising approach to improve care and keep patients safer," said Avner Halperin, CEO of EarlySense. We are honored that the EarlySense technology can determine respiratory patterns and provide clinicians with advanced tools to intervene effectively and, if required, early as evidenced in this study."

About EarlySense
EarlySense has brought to market an innovative technology designed to advance proactive patient care and empower clinicians to achieve better patient outcomes. Through early detection, the EarlySense system assists clinicians in identifying and preventing potential adverse events. It does so by providing motion rates and bed exit alarms, to help reduce falls and pressure ulcers, as well as surveillance of heart and respiratory rates to potentially detect patient deterioration. The company's flagship product, the EarlySense System, is a continuous, contact-free, patient safety monitoring solution that monitors and documents a patient's vital signs and movement using a sensor that is placed underneath a bed mattress. There are no leads or cuffs to connect to the patient who has complete freedom of movement and is not burdened by any cumbersome attachments. The system was designed to monitor patients on medical surgical floors who are usually monitored by nursing staff approximately once every four hours. The system is currently installed at hospitals and rehabilitation centers in the USA and Europe. It is also commercially available in Canada. Hospital administrators report that patients, their families and staff feel more comfortable knowing the system is in place. EarlySense Inc. is headquartered in Waltham, MA. 

Follow us on Twitter.
Like us on Facebook.


'/>"/>
SOURCE EarlySense
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CRLX101 Meets Primary Endpoint in Phase 2 Clinical Trial in Relapsed Ovarian Cancer
2. Seres Health Announces Interim Clinical Data for SER-109 in Recurrent C. difficile
3. Concordia Healthcare Corp. announces FDA agreement on Special Protocol Assessment for Phase 3 Clinical trial on new therapy to treat perihilar cholangiocarcinoma
4. EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA
5. arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire
6. Kaiser Permanente-Led Team to Become Integral Part of New National Clinical Research Network
7. Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
8. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
9. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
10. Croissance Clinical Research Collaborates with Acceliant for Clinical Trial Excellence
11. BioSpecifics Technologies Corp. Announces Positive Top-line Data from Phase 2 Clinical Trial of CCH for the Treatment of Human Lipoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical , ... company with their  2017 New Product Innovation Award for ... extensive primary and secondary medical device market research by Frost ... its first-to-market OTC, drug-free pain relief product, the AVACEN 100, ... to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):